Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CSTL NASDAQ:FLGT NASDAQ:PSNL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$18.74-24.3%$25.62$14.59▼$44.28$559.04M1.11386,000 shs1.31 million shsFLGTFulgent Genetics$14.96+0.2%$15.98$13.46▼$31.04$444.42M0.88499,674 shs296,199 shsPSNLPersonalis$5.90-2.9%$6.97$3.84▼$11.50$615.52M1.961.58 million shs830,459 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+0.61%+2.10%+0.08%-23.61%+48.92%FLGTFulgent Genetics+0.13%+0.81%-9.14%-37.07%-20.72%PSNLPersonalis+9.17%+20.44%-7.75%-18.08%+51.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCSTLCastle Biosciences$18.74-24.3%$25.62$14.59▼$44.28$559.04M1.11386,000 shs1.31 million shsFLGTFulgent Genetics$14.96+0.2%$15.98$13.46▼$31.04$444.42M0.88499,674 shs296,199 shsPSNLPersonalis$5.90-2.9%$6.97$3.84▼$11.50$615.52M1.961.58 million shs830,459 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCSTLCastle Biosciences+0.61%+2.10%+0.08%-23.61%+48.92%FLGTFulgent Genetics+0.13%+0.81%-9.14%-37.07%-20.72%PSNLPersonalis+9.17%+20.44%-7.75%-18.08%+51.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCSTLCastle Biosciences 2.90Moderate Buy$46.00145.46% UpsideFLGTFulgent Genetics 2.20Hold$27.0080.52% UpsidePSNLPersonalis 2.57Moderate Buy$11.5095.08% UpsideCurrent Analyst Ratings BreakdownLatest FLGT, PSNL, and CSTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026CSTLCastle Biosciences Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$44.00 ➝ $43.005/5/2026FLGTFulgent Genetics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$30.00 ➝ $15.004/27/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/21/2026PSNLPersonalis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CSTLCastle Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.003/5/2026PSNLPersonalis Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$11.00 ➝ $10.003/2/2026CSTLCastle Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy3/2/2026CSTLCastle Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold2/27/2026CSTLCastle Biosciences Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$41.00 ➝ $44.002/27/2026PSNLPersonalis Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $12.002/11/2026PSNLPersonalis BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $13.00(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCSTLCastle Biosciences$344.23M1.65$0.85 per share22.10$16.13 per share1.16FLGTFulgent Genetics$320.35M1.39N/AN/A$35.10 per share0.43PSNLPersonalis$69.65M8.86N/AN/A$2.94 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCSTLCastle Biosciences-$24.16M-$0.85N/AN/AN/A-7.02%-0.89%-0.74%N/AFLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%N/APSNLPersonalis-$81.27M-$0.91N/AN/AN/A-116.69%-39.13%-29.31%5/7/2026 (Confirmed)Latest FLGT, PSNL, and CSTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026PSNLPersonalis-$0.23N/AN/AN/A$14.49 millionN/A5/6/2026Q1 2026CSTLCastle Biosciences-$0.49-$0.49N/A-$0.49$79.23 million$84.23 million2/27/2026Q4 2025FLGTFulgent Genetics$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million2/26/2026Q4 2025CSTLCastle Biosciences-$0.23-$0.08+$0.15-$0.08$81.19 million$81.88 million2/26/2026Q4 2025PSNLPersonalis-$0.31-$0.26+$0.05-$0.26$17.12 million$17.35 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCSTLCastle BiosciencesN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCSTLCastle Biosciences0.025.265.11FLGTFulgent GeneticsN/A5.316.48PSNLPersonalisN/A6.766.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCSTLCastle Biosciences92.60%FLGTFulgent Genetics48.06%PSNLPersonalis61.91%Insider OwnershipCompanyInsider OwnershipCSTLCastle Biosciences6.10%FLGTFulgent Genetics36.18%PSNLPersonalis4.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCSTLCastle Biosciences54030.30 million28.45 millionOptionableFLGTFulgent Genetics1,31529.75 million18.99 millionOptionablePSNLPersonalis400104.68 million100.28 millionOptionableFLGT, PSNL, and CSTL HeadlinesRecent News About These CompaniesPersonalis, Inc. (NASDAQ:PSNL) Receives $11.50 Consensus PT from AnalystsMay 5 at 4:10 AM | americanbankingnews.comPersonalis, Inc. $PSNL Shares Sold by AIGH Capital Management LLCMay 2, 2026 | marketbeat.comPersonalis (NASDAQ:PSNL) Stock Price Up 12.5% - Still a Buy?April 30, 2026 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of "Moderate Buy" from AnalystsApril 30, 2026 | marketbeat.comPersonalis (PSNL) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comPersonalis (NASDAQ:PSNL) Trading Down 8.1% - What's Next?April 28, 2026 | marketbeat.comPersonalis to Announce First Quarter 2026 Financial ResultsApril 23, 2026 | finance.yahoo.comPersonalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026April 21, 2026 | businesswire.comPersonalis (NASDAQ:PSNL) Stock Price Down 6.2% - Here's What HappenedApril 20, 2026 | marketbeat.comPersonalis (NASDAQ:PSNL) Shares Up 6.8% - What's Next?April 13, 2026 | marketbeat.comPersonalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026April 13, 2026 | businesswire.comPersonalis (NASDAQ:PSNL) Stock Price Down 8.4% - Here's What HappenedApril 7, 2026 | marketbeat.comPersonalis, Inc. (NASDAQ:PSNL) Receives Consensus Recommendation of “Moderate Buy†from AnalystsApril 5, 2026 | defenseworld.netDPersonalis Appoints Dr. Richard Chen as President to Further Accelerate MRD AdoptionMarch 17, 2026 | businesswire.comPersonalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®March 12, 2026 | finance.yahoo.comPersonalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®March 12, 2026 | businesswire.comBreaking Down Personalis: 5 Analysts Share Their ViewsFebruary 27, 2026 | benzinga.comPersonalis outlines 170% clinical test volume growth target for 2026 as reimbursement and MRD strategy accelerateFebruary 27, 2026 | seekingalpha.comPersonalis (PSNL) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | finance.yahoo.comPersonalis, Inc. (PSNL) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comPersonalis: Q4 Earnings SnapshotFebruary 26, 2026 | seattlepi.comSNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGT, PSNL, and CSTL Company DescriptionsCastle Biosciences NASDAQ:CSTL$18.74 -6.01 (-24.28%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.Fulgent Genetics NASDAQ:FLGT$14.96 +0.04 (+0.25%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Personalis NASDAQ:PSNL$5.90 -0.18 (-2.88%) As of 01:57 PM Eastern This is a fair market value price provided by Massive. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Nuts and Bolts AI Play Gains Momentum: Astera Labs Targets Raised Anheuser-Busch Stock Jumps as Volume Growth Signals Turnaround Light Speed Returns: Corning Cashes In on NVIDIA Growth Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
